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Abstract 
The objective of this work was to develop solid dosage forms using powders containing inclusion 
complexes (ibuprofen with β-cyclodextrin) which were used to produce tablets (direct compression 
without additional excipients) and pellets (extrusion/spheronization) from wet mass containing 40% 
(w/w) of microcrystalline cellulose. The pellets also demonstrated that during preparation of the wet 
mass, the inclusion process occurred in a same yield that when pre-complexation was used. The 
particles characteristics were evaluated after being obtained through different complexation 
methods. The results showed that the tensile strength and profile dissolution were as expected for 
both dosage forms. Tablets containing inclusion complexes showed higher solubility when 
compared with a reference formulation and with two commercial formulations. The ibuprofen 
released from the two pellets formulations didn’t show relevant differences between them. The drug 
released was analyzed considering different dissolution parameters. The advantages of these new 
methodologies can be summarized as: (a) tablets were produced at a lower cost for the total process; 
and (b) in the pellet´s preparation there was no need of the previous complexation method resulting 
in a decrease in time and energy required. 
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1. Introduction 
 Drugs to be incorporated into solid dosage forms should present high water solubility and 
high permeability throughout the gastrointestinal mucosa, like the ones belonging to Class I 
(Biopharmaceutical Classification System, BCS) [1]. Consequently all drugs that do not present 
such characteristics have to be transformed (chemically or physically) to improve solubility and/or 
permeability. For Class II, the drug´s (e.g. Ibuprofen - IB) [2] solubility in aqueous media affects its 
release and thus the bioavailability may also be affected negatively. Some technologies used to 
increase drug solubility can lead to changes in their particles characteristics and thus influence the 
processability, stability and bioavailability of the solid dosage forms made from them. 
 The complexation of a drug with cyclodextrins (CDs) is a commonly used method to 
improve its solubility [3,4]. Cyclodextrins are cyclic oligosaccharides consisting of six, seven or 
eight glucose molecules looking like a truncated cone or torus. The torus presents an external 
hydrophilic surface that facilitates an easy dissolution in water, whereas its cavity is far less polar 
allowing the interaction with the non-polar parts or the whole molecules of approximately its size, 
leading to the formation of the inclusion complexes [3,4]. 
The literature describes different techniques to form complexes with cyclodextrins, all leading to an 
improvement in the drugs´ solubility, when compared with pure drugs´ solubility [3-7]. Several 
studies performed by other authors showed the feasibility of the various processes of complexation 
in the inclusion complex formation between IB and βCD. The different results corroborated the 
inclusion complex formation and showed that the particles characteristics were dependent of the 
complexation methods [8-13]. These characteristics (shape, size distribution, crystalline or 
amorphous state) can influence the processing of the solid dosage form and subsequently the release 
of the drug in water. The inclusion complexes obtained by different technologies can be regarded as  
raw materials in the preparation of the solid dosage forms, and their compactibility, extrudability 
and dissolution profiles are dependent on the characteristics of both the inclusion complex particles 
and the dosage form [7,8]. 
 The aim of this study was to analyze the possibility of producing tablets from powders 
containing inclusion complexes, without using additional excipients, and the ability of forming 
inclusion complexes (IBβCD) during wetting of the extrusion mass in the pellets´ production. The 
particles´ characteristics were evaluated after being obtained through different complexation 
methods. Moreover, for both tablets the IB released was compared in between them and also with 
the ones observed with commercial formulations. The IB released was also compared for both 
pellets formulations. 
 
2. Materials and methods 
2.1. Materials 
 The model drug chosen for this study was (±)-Ibuprofen, (racemic α-methyl-4-[2-
methylpropyl] benzene acetic acid, IB), a practically insoluble in water drug (supplied by Capsifar, 
Portugal). For the preparation of the solid dosage forms β-cyclodextrin (Wacker, Germany, βCD), 
lactose (Granulac 200 Meggle, Germany, LAC) and microcrystalline cellulose (Avicel PH 101, 
FMC Biopolimer, Ireland, MCC) were used. A generic and a brand name, non-coated commercially 
available tablets with 200 mg IB were used for comparison, respectively Com1 (mean mass ± 
standard deviation: 269.0 ± 3.31 mg) and Com2 (366.9 ± 8.37 mg). Hydrochloric acid solution (pH 
1.0) was used as dissolution medium [14]. 
4 
 
 
2.2. Methods 
2.2.1. Preparation of the inclusion complexes 
 The preparation of the inclusion complexes (IBβCD K70 and IBβCD FD) was described in a 
previous study [5] (Table 1). Briefly, IB and CD were mixed in a 1:1 stoichiometric proportion 
(molar ratio) and water was added: either 70% w/w (K70), i.e., kneading or in such a quantity to 
produce a suspension/solution (1.63 x 10-2 M at 25 ºC for βCD). The kneaded mass was dried in the 
preparation mortar whereas the suspension/solution was dried by freeze-drying (Christ Alpha 1-4, 
B. Braun Biotech International, Germany: the samples were previously frozen at -20 ºC and then 
dried at 4.5-7.0 µbar for 48 hours). The powders obtained were sieved (Retsch, Germany) and, if 
required, milled to produce particles with less than 250 µm considered for tabletting and 
pelletization. 
 
Table 1 
Composition of powder mixtures with ibuprofen. 
Ibuprofen Preparation method Water removal 
IBLAC powder mix not applicable 
IBβCD K70 kneading with 70% of water paste formation 
IBβCD FD suspension/solution freeze-drying 
 
2.2.2. Preparation of the reference mixture 
 A mixture containing IB with LAC was produced in a tumble mixer for 10 min 
(Fisher-Kendall Scientific Co, USA) (Table 1). 
 
2.2.3. Characterization of the inclusion complexes and reference mixture 
 The mixtures IBβCD K70 and IBβCD FD were characterized in a previous study [5] by 
optical microscopy (OM), differential scanning calorimetry (DSC), ultraviolet spectroscopy (UV), 
infrared with Fourier Transformer (FTIR), nuclear magnetic resonance (NMR) and X-ray diffraction 
(XDPR) in order to prove the existence of inclusion complexes and their complexation 
stoichiometry [10]. In this study the raw materials (IB, βCD and LAC) and powder mixtures 
(IBLAC, IBβCD K70 and IBβCD FD) were observed by electron microscope (JEOL-JSM-S200LV 
Scanning Microscope, JOEL-JFC-1200 Fine Coater, USA) on a magnification 100, 350 and 1,500 
X. The bulk and tapped densities were assessed by measuring cylinder (50 cm3) [14]. The parameter 
Carr index (ICr) [15] was determined using the following equation: 
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where, D0 is the initial bulk density and Df is the tap bulk density. The true density was determined 
by helium pycnometry (AccuPyc 1330, Micromeritics, USA). The flow properties of the powders 
were examined with an Erweka GT Granule tester (Erweka, Germany): powders were poured into a 
funnel and then allowed to pass through a nozzle of 15 mm diameter onto plate for 10 s. The angle 
of repose was calculated as the angle of the powder’s cone to the plate. 
 
2.2.4. Preparation of tablets and pellets 
 Tablets (1300 mg powder containing 200 mg IB) were prepared for all mixtures shown in 
Table 1 in an universal testing machine (Lloyd Instruments LR 50K, UK) with a 50 kN load cell 
allowing the recording of the force and displacement of 13 mm diameter punches. The compaction 
force applied was 10.0 kN with an upper punch speed of 10 mm/min. This load was chosen as the 
maxim limit to influence the volume reduction behavior, particle size and compaction load on 
bonding mechanisms. The chosen dose corresponds to the lowest adult’s commercial dosage. This 
small dose still allows the production of tablets with appropriate dimensions. 
 Pellets with and without inclusion complexes were produced by extrusion/spheronization 
[16-18] where the microcrystalline cellulose (MCC) was used as extrusion/spheronization excipient. 
The powders for the preparation of the pellets were mixed in the ratio (w/w) of 40 parts of the MCC 
and 60 parts of the IB and βCD (1:1 molar ratio) (PL) for 5 min in a planetary mixer (Kenwood 
Chief, UK). Another mixture (40:60) was made of IBβCD K70 instead individual weighing of the 
IB and βCD and was designed PL K70. For the two formulations the appropriate quantity of water 
(55% w/w), was slowly added to the powders and kneaded for 10 min. Approximately 100 g of 
each wet mass was packed manually into the barrel of a ram extruder and fit with a 1 mm diameter 
die. The ram extruder was attached to an universal testing machine (Lloyd Instruments LR 50K, 
UK) operated at 100 mm/min. Spheronization of extrudates was carried out in a spheronizer fit with 
a crosshatch plate (GB Caleva, Model 230, UK) rotating at 1000 rpm for 20 min. The pellets were 
dried in a fluidized bed (Aeromatic-Fielder AG, Switzerland) at 45 ºC for 30 min. The 1.0-1.4 mm 
fractions were used in the study. 
 
2.2.5. Tablets and pellets crushing and tensile strength  
 The crushing strength (CT5, Engineering systems, UK) of both tablets and pellets was found 
by the application of maximum loads of 490 N and 49 N, at a 6.9 mm/min displacement, 
respectively. The tensile strengths for tablets and pellets were calculated from the following 
equations [19,20]: 
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where, F is the force applied to the sample, D and h the diameter and height of the tablet, 
respectively and r the pellet radius. 
 
2.2.6. Dissolution studies 
 In vitro drug release was monitored taking into consideration the dissolution test described 
in the European Pharmacopoeia [14], paddle method (50 rpm) using a dissolution apparatus (Sotax 
model AT7, Switzerland) containing 1000 ml of hydrochloric acid solution pH 1.0. The pH used 
corresponds to drastic conditions for IB solubility to allow comparison between references and 
processed powders. The IB released was quantified in a UV–Vis spectrophotometer (U-200, 
Hitachi, Japan) set at 221 nm (βCD has no significant absorption [21]), at predetermined times (10, 
20, 30, 40, 60, 90, 120, 180 and 1440 min - the last value was chosen to allow the comparison of the 
total IB released, between dosages forms with inclusion complexes and references). The cumulative 
fraction of the drug released was calculated from the total amount of IB and plotted as a function of 
time (n = 3). Pellets and tablets, both commercial and produced as described, containing 200 mg IB 
were weighted and placed in each dissolution vessel (using no sink conditions).  
 The data from the release of IB was analyzed using different dissolution parameters, 
namely, comparison of the amounts released at determined times (Mtmin), the efficiency of 
dissolution (DE) and the similarity factor (f2) [22]. Dissolution data, at some time points (Mtmin) (30, 
60 and 180 min) was compared statistically by ANOVA and by post-hoc Tukey test (SPSS 
Statistics 17.0, SPSS Inc., Chicago, USA), at α = 0.05 significance level. 
 
3. Results and Discussion 
3.1. Powders and reference mixtures 
 The particles shape is a parameter that can influence some pharmaceutical properties of the 
raw-materials as well as the processed products (flux, rearrangement in the die). The number and 
strength of the bounds created between particles during formulation processes (granulation, 
compactation) is also related with the particles´ shape. These factors determine the quality of the 
solid dosage forms and consequently the drug release behavior in water. 
 The observation of particles by electronic microscopy has shown differences between 
particles (Fig.  1). IB particles presented a rod shaped form with smooth surfaces (Fig. 1, top), like 
βCD presenting a cubic shape with smooth surfaces (Fig. 1, middle). On the other hand, LAC 
particles present irregular forms and rough surfaces (Fig. 1, bottom). Fig. 2 shows the particles 
produced for the reference mixture (Fig. 2, top, IBLAC) which is a mixture of particles of raw 
materials with different sizes and shapes, as described for IB and LAC (Fig. 1). Particles´ shapes 
and sizes for this reference mixture didn´t change after mixing. For IBβCD K70 and IBβCD FD 
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mixtures the complexation methods and their drying processes generated particles with other 
morphologies, different from the raw materials particles from which they were originated (Fig. 2, 
middle and bottom). However, some rod shaped particles can still be seen in those mixtures, which 
correspond to a low amount of pure IB. These observations confirm as previously referred in 
another study [5], that a different entity (inclusion complex) was formed. IBβCD K70 showed 
rough and cubic particles, whereas IBβCD FD showed more elongated particles. It must be pointed 
out that the sizes and shapes of particles were also affected by the technique considered for the 
formation of the complex (kneading or suspension/solution), drying (freeze-drying or simple 
evaporation by exposure to dried air during the kneading process) and grinding. This means that 
morphology changes might have happened due to complexation but other techniques must prove the 
formation of the complex, namely NMR, FTIR, XRPD, as described previously [5]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1. Scanning electron micrographs of raw-material (IB, βCD, LAC). 
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β-ciclodextrin 
   
Lactose 
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Fig. 2. Scanning electron micrographs of reference (IBLAC) and inclusion complexes (IBβCD 
K70, IBβCD FD) mixtures. 
 
 The apparent and tap densities of the raw materials (Table 2) showed that the IB is the 
material with higher interparticle porosity [15,23]. The values of βCD are largely in line with those 
presented in the literature (0.42-0.59 and 0.74-0.76 g/cm3 for the apparent and tap densities, 
respectively [3]. 
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Table 2 
Results for the bulk, tap and true densities, compressibility index and angle repose of powdersa). 
Raw-materials 
D0 
(g/cm3) 
Df 
(g/cm3) 
ICr 
(%) 
ρ 
(g/cm3) 
Angle of repose 
(º) 
IB 0.29 0.51 43.00 1.12 57.17 
βCD 0.54 0.75 28.00 1.48 47.80 
LAC 0.53 0.89 41.00 1.55 51.53 
Mixtures with IB      
IBLAC 0.55 0.85 36.00 1.46 49.40 
IBβCD K70 0.51 0.74 31.00 1.41 49.93 
IBβCD FD 0.22 0.39 44.00 1.48 58.47 
The coefficient of variation was below 1% for all cases 
D0 = bulk density 
Df = tap density 
ICr = compressibility index 
ρ = true density 
a)
 results are the mean of 3 measurements (n = 3) 
 
 The powder with a larger interparticle porosity is the one obtained by removal of the water 
by freeze-drying (IBβCD FD). Freeze-drying leads to products with higher porosity and high 
amorphous content than other processes [3,24]. The densities of the reference mixture (IBLAC) 
showed values very similar to the original components, i.e., close to the component that existed in 
larger quantities (LAC). For powders made of inclusion complexes, the apparent densities were 
variable depending mainly on their ability to flow and ease on the manual filling of the die in the 
compaction process, as shown by the Carr’s index and angle of repose determinations (Table 2). 
These powders can be regarded as poor flowing materials [15,23,25]. 
 The results for the true densities showed small differences between the IBβCD K70 and 
IBβCD FD samples resulting from the complexation methods. For IBβCD FD mixture the measured 
density (1.48) was higher than the expected density (1.42) [26] resulting in the possible decrease of 
the intraparticle porosity. The expected density (g/cm3) for the IBβCD FD mixture (1:1) was 
calculated using the following expression: 
 
(% drug x true density of drug) + (% βCD x true density of βCD)                     (4) 
using helium pycnometry (AccuPyc 1330, Micromeritics, USA). 
 
3.2. Tablets and pellets 
3.2.1. Compaction profiles 
 The compaction profiles of the tablets obtained from compressing each mixture are shown 
in Fig. 3 reflecting a well known logarithmic relationship between the displacement of the punch 
and the force applied. Although the profiles were not too different, one can differentiate between 
both the IBLAC and IBβCD K70 and the IBβCD FD. The later has shown a smoother increase on 
the force suggesting that the materials did better accommodate the force applied at early stages of 
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compression than the other two. This might have happened as a consequence of a higher porosity 
between particles (not within particles) that made difficult the repacking of these particles [7,24,27- 
29] and this is reflected by the highest energy of compaction (area under the force versus 
displacement curve) which was 20.7 J. For other mixtures (IBβCD K70 and IBLAC) the values 
were 12.5 J and 9.0 J, respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3. Compaction profiles for the different mixtures at 10 kN load. 
 
3.2.2. Extrusion profiles and spheronization 
 The extrusion profiles for the wet masses of PL (MCC + IB + βCD) and PL K70 (MCC + 
IBβCD K70) can be seen in Fig. 4. The profiles show a similar compaction phase but the steady-
state phases are different. Although the energies of extrusion were similar (1.13 KJ and 1.21 KJ for 
PL and PL K70, respectively), the tendencies of both curves were opposite: while the profile for PL 
kept increasing with extrusion the PL K70 profile decreased before the forced flow phase. It 
suggests that the two materials presented a different degree of lubrication, with the PL K70 being 
more lubricated than PL. This observation is coherent with the production of the masses: the same 
amount of water was added to both materials but the PL K70 was already exposed to water 
throughout the complex formation phase. It might be pointed out that the water required for 
extrusion might have promoted the formation of the complex in PL extrudates [17]. 
 Spheronization of extrudates produced pellets with high sphericity and narrow size 
distribution: 67% and 66% for pellets within 1.0 and 1.4 mm diameter were collected for PL and PL 
K70 formulations, respectively. 
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Fig. 4. Extrusion profiles of two wet mass formulations (PL and PL K70). 
 
3.2.3. Crushing and tensile strengths 
 The tensile strength for both tablets and pellets formulas is shown in table 3. The results for 
the processed formulations showed that IBβCD FD tablets had a higher strength than others. The 
amorphous state and higher surface of the particles that characterized the IBβCD FD mixture due to 
the freeze drying process, associated with high compaction force explains this result through the 
increase of the links between particles [24,29]. For the pellets this parameter showed differences 
between two formulations. The formulation containing the binary mixture previously obtained by 
the complexation method, produced pellets with greater resistance than the other formulation. The 
strength value for this dosage form is approximately 2 times higher. The kneading procedure 
promotes the formation of bounds which are intensified during the preparation of the wet mass. 
 
Table 3 
Tensile strengths and disintegration times for both tablets and pelletsa) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Tensile Strength 
(MPa) 
Disintegration 
(min) 
 Tablets Pellets Tablets/ Pellets 
IBLAC 0.21 ± 0.01  1.00 
IBβCD K70 1.17 ± 0.12  1.70 
IBβCD FD 1.46 ± 0.19  >60.00 
Com1 8.75 ± 0.78  43.50 
Com2 b)  1.70 
PL  0.050 ± 0.08 c) 
PL K70  0.103 ± 0.05 c) 
a)
 mean ± standard deviation (n = 3)  
b) not determined 
c)
 no disintegration 
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3.2.4. Dissolution tests 
 The dissolution profiles of the tablets and pellets carried out in dissolution medium pH 1.0 
can be seen in Fig. 5. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5. Dissolution profiles of the tablets and pellets formulation at 180 and 1440 min. 
 
 The dissolution profiles for the tablets formulations showed that IB under the form of 
inclusion complex (IBβCD K70 and IBβCD FD) presented higher solubility than IB not complexed 
(IBLAC). This fact confirms that the preparation methods used to produce the inclusion complex 
were efficient [5]. The difference between the two profiles in the first 180 min was due to the 
difficulty of the IBβCD FD tablet disintegration (Table 3) for the reasons presented in 3.2.3. These 
tablets after 1 h presented only a slight disintegration. The particles´ characteristics resulting from 
the drying method (freeze-drying) explains the releasing behavior of these tablets [8,11,24,28]. On 
the other hand, the quick disintegration of the IBβCD K70 tablets exposes the particles of the 
inclusion complexes with the dissolution medium.  
 The amount of inclusion complex that exists in the two tablets formulations is almost the 
same as was presented in a previous work which concluded that the amount of  water isn´t an 
important parameter for the complexation yield [5]. At 1440 min both profiles reached 100% IB 
which corroborated the study cited [5]. The reference tablet (IBLAC) showed a dissolution profile 
similar with two commercial formulations which didn´t reach 100% of the drug released (plateau at 
180 min <> approximately release of 30%) due to the non existence of IB in the inclusion complex 
form. The IB corresponding to the intrinsic solubility released from these tablets lead to the 
saturation of the dissolution medium. 
 The dissolution profiles for the pellets formulations showed only small differences in 
between them. This observation confirmed that during the preparation of the wet mass, necessary 
for the extrusion procedure, the formation of the inclusion complex occurred with practically the 
same yield as obtained with the kneading method. The IB released from this dosage form 
corresponds to a prolonged release, as suspected due to the presence of MCC in the formulation 
and, is different to the release obtained with tablets [8,17,30]. The pellets did not disintegrate 
throughout the time of test, as expected [17,18]. 
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 As for the tablets, the IB released from the pellets reached almost 100% at 1440 min. The IB 
released (100% <> 1440 min) for both dosage forms containing inclusion complexes showed a 
greater yield in the complexation method that corroborates the results obtained in a previous work 
[5]. The results showed an increase in the IB solubility due to the formation of the inclusion 
complex when compared with references (IBLAC and commercials forms). The various dissolution 
parameters of the tablets and pellets are shown in Table 4. 
 The values presented for the ED parameter (Table 4) obtained from different tablets showed 
a larger difference between IBβCD K70 and other tablet formulations (IBβCD FD, reference and 
both commercial forms) at time 30 min. The presence of IB as an inclusion complex is responsible 
for the difference between the reference formulation (IBLAC) and the commercial formulations 
(Com1 and Com2). The characteristics of the particles resulting from the method of preparation and 
the quick disintegration of the IBβCD K70 tablet made the difference from the other formulation 
(IBβCD FD) [8,30,31]. For the other times considered (60 and 180 min) results have shown a more 
pronounced increase in the IB released from IBβCD FD tablets. For the other tablets only small 
increases were observed and the release was not complete due to the absence of the complex, thus 
the IB released did saturate the dissolution medium. 
 
Table 4 
Dissolution parameters used ibuprofen tablets and pellets at pH 1.0. 
 Mtmin  (%)ª) DE (%) f2 (%) 
 30 60 180 30 60 180   
IBLAC 7.58 ± 0.21 12.84 ± 0.86 23.46 ± 0.66 4.04 7.20 14.84 (100.00)  
IBβCD K70 89.26 ± 1.85 97.06 ± 1.66 99.09 ± 1.66 61.58 77.52 91.25 5.52  
IBβCD FD 6.71 ± 0.66 21.88 ± 0.59 86.10 ± 0.97 3.31 8.33 43.66 25.97  
Com1 16.84 ± 0.74 25.26 ± 0.36 29.85 ± 0.21 7.47 14.62 24.09 51.31  
Com2 10.94 ± 0.20 18.85 ± 0.79 30.03 ± 1.30 5.78 10.48 20.51 63.37  
PL 20.29 ± 0.08 32.22 ± 1.11 54.05 ± 1.28 11.19 18.83 37.57 34.02 (100.00) 
PL K70 23.07 ± 0.41 36.66 ± 0.30 71.10 ± 2.68 13.26 21.70 44.39 27.97 56.80 
a)
 mean ± standard deviation (n = 3) 
 
 The similarity factor (f2) for the Com1 and Com2 formulation showed similarities with the 
IBLAC reference tablets with values above 50. Other tablets formulations didn´t show to be similar 
due to the existence of the inclusion complexes. 
 Amounts of the IB released (%) for 30, 60 and 180 min for all the tablets formulations 
showed the same differences as discussed above. The release of IB increased, reaching 99.1% for 
IBβCD K70 and 86.1% for IBβCD FD formulation at time 180 min. After this time interval, the 
release of the IB for the reference and commercial tablets increased only slightly, resembling a 
plateau. 
 The dissolution parameters for the pellets formulations showed an increase in solubility of 
the IB which confirms the existence of the inclusion complexes. The similarity factor (f2) for both 
formulations (time 180 min) showed similarity between them with values above 50. 
 The amounts of drug released at the time 30, 60 and 180 min were statistically evaluated for 
all formulations. The results for the tablets showed no statistically significant differences for 
IBLAC and IBβCD FD formulations at time 30 min and Com1 and Com2 formulations at time 180 
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min. The IBβCD FD at time 180 min showed statistically significant differences compared with 
IBLAC and commercial formulations as previously explained. The IBβCD K70 tablets showed at 
time 30 and 60 min large differences in the drug release comparatively with the others formulations. 
This is due to the easy disintegration of the tablet and consequent exposition of the inclusion 
complex to the dissolution medium. This rapid disintegration made the difference from IBβCD FD 
tablets (because the existence of inclusion complex) with IBLAC, Com1 and Com2 tablets. 
 The pellets formulations showed differences with all other formulations because they are 
dosage forms of prolonged release. The increasing release of IB over time shows the existence of 
the inclusion complex. 
 
4. Conclusions 
 This study showed that it is possible to produce tablets and pellets using powders mixtures 
containing inclusion complexes prepared by different complexation methods. The tablets were 
produced without additional excipients while in the pellets only MCC was used in the preparation 
of the wet mass. Throughout this study it was also possible to demonstrate that there is an increase 
of IB solubility (through dissolution profiles) from tablets and pellets in pH 1.0. The tablets release 
profiles were compared with a reference formulation and two commercial formulations showing 
large differences between them. The best formulations were IBβCD K70 and IBβCD FD due to the 
existence of the inclusion complex that allowed a 100 % release of the drug. These dosage forms 
were produced without additional excipients. However, in the scale up transposition, small amounts 
of a lubricant, glidant and disintegrant will need to be added to facilitate the process (rotatory 
machine) and to improve the quality of the tablets. 
 
 The release profiles of the pellets formulations showed that it´s not necessary to carry out 
the previous complexation process because the inclusion occurs, with practically the same yield, 
during the preparation of the wet mass. This observation is important for the industrial production. 
The profiles from both formulations showed a slow IB release (due MCC) when compared with 
tablets profiles, reaching almost 100% at a time lower than 1440 min. This fact proves that the 
inclusion complex exists in great amount in pellets formulations. 
In other formulation (reference formulation) an inclusion complex between IB and βCD do not exist 
and so the saturation of the medium with the drug occurred, which can be seen by the fact that they 
didn’t reach the 100% drug release at final time of 1440 min. 
 These new methodologies for the scale up allow significant cost savings on both processes 
(less energy and time consumption and fewer ingredients and processing steps involved in the 
tablets production and elimination of the previous complexation method for the pellets) with the 
consequent decrease in time and energy required. 
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